Advances in the Management of ADHD in Adult Population

David W. Goodman, MD; Greg Mattingly, MD; and Birgit H. Amann, MD, provide an overview of ADHD, including its pathophysiology as well as its prevalence in the pediatric and adult populations.

Drs David W. Goodman, Rakesh Jain, Greg Mattingly, and Theresa R. Cerulli, discuss continuation of ADHD from childhood as well as data on remission of ADHD in adulthood.

Birgit H. Amann, MD; Rakesh Jain, MD, MPH; David W. Goodman, MD; Greg Mattingly, MD; and Theresa R. Cerulli, MD, share insight on the impact of ADHD on quality of life in adult patients.

Experts in the management of ADHD comment on unmet needs in disease management in the areas of diagnosis, treatment, and coverage of symptoms.

Drs Birgit H. Amann, David W. Goodman, and Greg Mattingly discuss signs and symptoms that may prompt testing for adult ADHD and share their considerations for approaching diagnosis.

Greg Mattingly, MD; David W. Goodman, MD; Birgit H. Amann, MD; and Theresa R. Cerulli, MD, evaluate the role of pediatric ADHD guidelines and common misconceptions in the diagnosis and treatment of ADHD.

Birgit H. Amann, MD, and Greg Mattingly, MD, review patient and provider goals of treatment and provide insight on evaluating response to treatment for ADHD.

Experts in ADHD discuss the benefits and challenges of telehealth on the diagnosis and management of adult ADHD.

Rakesh Jain, MD, MPH, leads a discussion on factors that guide treatment selection for adult patients with ADHD.

Rakesh Jain, MD, MPH, explores the role of an integrative treatment approach in regard to nonpharmacological treatment for the management of adult ADHD.

Dr David W. Goodman reviews the efficacy and tolerability of different classes of medications for the management of ADHD.

Birgit H. Amann, MD; Rakesh Jain, MD, MPH; Theresa R. Cerulli, MD; and David W. Goodman, MD, share unmet needs and risks in the treatment of adult ADHD.

Greg Mattingly, MD, and David W. Goodman, MD, discuss the recent approval of viloxazine in children and its clinical profile in the pediatric and adult populations in ADHD.

Key opinion leaders in the management of ADHD comment on where they anticipate using viloxazine and other nonstimulants in the ADHD treatment landscape.

Birgit H. Amann, MD, and Greg Mattingly, MD, share strategies for mitigating adverse events with viloxazine in ADHD and its effect on metabolism of drugs.

David W. Goodman, MD, leads a discussion on the use of viloxazine for the treatment of adults with ADHD.

Drs Rakesh Jain, Greg Mattingly, David W. Goodman, Birgit H. Amann, and Theresa R. Cerulli, discuss emerging agents in the pipeline for the management of pediatric and adult ADHD.